Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 4 |
Unknown | 2 |
Small molecule drug | 2 |
Biological products | 1 |
Target |
Mechanism melanocortin receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date21 Jun 2019 |
Target |
Mechanism MC1R agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MC1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date26 Dec 2022 |
Sponsor / Collaborator |
Start Date15 Sep 2022 |
Sponsor / Collaborator |
Start Date30 Dec 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Bremelanotide Acetate ( melanocortin receptor ) | Sexual Dysfunctions, Psychological More | Approved |
PL-9643 ( MC1R x MC5R ) | Xerophthalmia More | Phase 3 |
PL-8177 ( MC1R ) | Colitis, Ulcerative More | Phase 2 |
PL-3994 ( NPRA ) | Heart Failure More | Phase 2 |
PL-8331 ( MC1R x MC5R ) | Immune-mediated uveitis More | Preclinical |